Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05932745
Other study ID # 2000035551_b
Secondary ID 2U54DA036151-11
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date November 2024
Est. completion date November 2025

Study information

Verified date May 2024
Source Yale University
Contact Danielle Davis, PhD
Phone 203-974-7607
Email danielle.davis@yale.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is an examination of the influence of cooling components of WS-3, WS-23, and menthol on the appeal and addiction potential of nicotine-containing e-liquids among adults.


Description:

The investigators will examine the influence of cooling components of WS-3, WS-23 (synthetic coolants) and menthol on the appeal and addiction potential of nicotine-containing e-liquids among adults. Participants will rate the flavor intensity, coolness, sweetness, and irritation/harshness, bitterness experienced using validated rating scales. 66 adult participants (18+ years of age) who are current e-cigarette users will participate in 3 laboratory sessions. Participants will receive 3 e-cigarette that contain cooling flavors and nicotine (59mg/ml nicotine salt) during the sessions. Participants will be randomized to receive one of the 3 menthol conditions (no-menthol, low menthol, high menthol) in combination three WS-3 conditions (no WS-3, low WS-3, high WS-3) and two WS-23 conditions (low WS-23, high WS-23). All participants will be exposed to all fifteen conditions across 3 lab sessions.


Read more »

Study Design


Related Conditions & MeSH terms


Intervention

Read more »

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Yale University National Institute on Drug Abuse (NIDA)

References & Publications (1)

Lim J, Wood A, Green BG. Derivation and evaluation of a labeled hedonic scale. Chem Senses. 2009 Nov;34(9):739-51. doi: 10.1093/chemse/bjp054. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Liking: Score change in liking/wanting of each e-cigarette condition (5 conditions in total) The Labeled Hedonic Scale will be used to ask about liking and wanting of the e-cigarette (one item Visual Analog Scale with ratings ranging from "most disliked sensation imaginable" to "most liked sensation imaginable" with higher values indicating greater liking). Following administration of e-cigarette condition 1 (at 10 minutes), following administration of e-cigarette condition 2 (at 40 minutes)...following administration of e-cigarette condition 5 (at 130 minutes)
Primary Reinforcing Efficacy: Score change in drug effects of each e-cigarette condition (5 conditions in total) Difference between e-cigarette effects for each e-cigarette condition as measured by the computerized version of the Drug Effects Questionnaire (DEQ). Participants will self-report their responses using a computer mouse to indicate where on the scale response falls. A modified version of the Drug Effects Questionnaire (DEQ) will be used in which participants rate acute responses to the e-cigarette on a 0-100mm scale from "not at all" (0mm) to "extremely" (100mm). Following administration of e-cigarette condition 1 (at 10 minutes), following administration of e-cigarette condition 2 (at 40 minutes)...following administration of e-cigarette condition 5 (at 130 minutes)
Primary Irritation/Harshness: Score change in irritation of harshness of each e-cigarette condition (5 conditions in total) Difference in irritation at each e-cigarette condition as measured by the computerized Generalized Labeled Magnitude Scale (gLMS). Participants will self-report their responses using a computer mouse to indicate where on the scale response falls. The Generalized Labeled Magnitude Scales (gLMS) are category ratio scales with seven semantic labels: "no sensation", "barely detectable", "weak", "moderate", "strong", "very strong", and "strongest imaginable", positioned quasi-logarithmically as per empirically determined semantic magnitudes on a 0-100 scale (strongest imaginable at the 100 end). Following administration of e-cigarette condition 1 (at 10 minutes), following administration of e-cigarette condition 2 (at 40 minutes)...following administration of e-cigarette condition 5 (at 130 minutes)
Secondary Craving: Change in craving score for e-cigarette from baseline at each e-cigarette condition (5 conditions in total) Difference from baseline in craving for each e-cigarette condition will be measured by the Generalized Labeled Magnitude Scale (gLMS). Participants will self-report their craving for e cigarettes using a computer mouse to indicate where on the scale response falls. The Generalized Labeled Magnitude Scales (gLMS) are category ratio scales with seven semantic labels: "no sensation", "barely detectable", "weak", "moderate", "strong", "very strong", and "strongest imaginable", positioned quasi-logarithmically as per empirically determined semantic magnitudes on a 0-100 scale (strongest imaginable at the 100 end). At baseline (at 0 minute), following administration of e-cigarette condition 1 (at 10 minutes), following administration of e-cigarette condition 2 (at 40 minutes)...following administration of e-cigarette condition 5 (at 130 minutes)
Secondary Changes of salivary Nicotine and Cotinine Levels from baseline at each e-cigarette condition (5 conditions in total) Saliva samples will be collected following each exposure to product and before each lab sessions to assess change in nicotine/cotinine levels. These levels will be used for correlational analyses with behavioral measures and will be determined using LC/MS techniques at the core laboratory of university. At baseline (at 0 minute), Following administration of e-cigarette condition 1 (at 10 minutes), following administration of e-cigarette condition 2 (at 40 minutes)...following administration of e-cigarette condition 5 (at 130 minutes)
See also
  Status Clinical Trial Phase
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Completed NCT02511704 - Pharmacokinetics and Acute Effects of Multiple Dose of Nicotine: Electronic Cigarette and Cigarette Phase 1
Completed NCT04568395 - Acute Effects of TCIG vs ECIG in PLWH N/A
Completed NCT03338933 - Neurobiology of Alcohol and Nicotine Co-Addiction
Completed NCT03634839 - Effects of E-cigarette Flavors on Youth TCORS 2.0 Phase 1
Recruiting NCT05515354 - Smoking Cessation and Menstrual Cycle Phase Phase 4
Withdrawn NCT06259630 - Nicotine Virtual Reality Conditioned Place Preference Phase 4
Recruiting NCT06170138 - Study to Assess PK, PD, Nicotine Extraction, Palatability, Subjective Effects of Nicotine Pouches - Daily Nicotine Users N/A
Not yet recruiting NCT03264755 - Cortical Excitability and Role of rTMS in Nicotine Use Disorder N/A
Recruiting NCT05766254 - Identify the Optimal TMS Target to Modulate Reward Activity N/A
Completed NCT00330187 - Combined Pharmaco/Behavior Therapy in Adolescent Smokers Phase 2
Completed NCT03635333 - Effects of E-Cigarette Flavors on Adults TCORS 2.0 Phase 1
Completed NCT03438188 - Neural Basis of Eating Behavior in Abstinent Smokers N/A
Completed NCT03194958 - Helping Poor Smokers Quit N/A
Recruiting NCT04432064 - Temporal Interference Neurostimulation and Addiction N/A
Recruiting NCT05181891 - Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking Phase 2
Completed NCT05897242 - A Smartphone Application (ACT on Vaping) for Vaping Cessation in Young Adults N/A
Not yet recruiting NCT05994209 - Testing the Feasibility and Acceptability of Social Media and Digital Therapeutics to Decrease Vaping Behaviors Phase 1
Completed NCT03302026 - Real Time fMRI and Quitting Smoking N/A
Terminated NCT03352609 - Accelerated rTMS for the Reduction of Nicotine Craving N/A